title: [Effect of bortezomib combined with bisphosphonates on bone metabolism index in multiple myeloma].
abstract: This study was aimed to investigate the effect of bortezomib combined with bisphosphonates on serum levels of DKK-1 and RANKL in multiple myeloma patients, and to evaluate its role in the therapy of osteolytic lesion. Fourty-three patients with newly diagnosed and relapsed myeloma were divided into 2 groups. Twenty-three patients were treated with bortezomib combined with bisphosphonates (A group) and 20 patients were treated with bisphosphonates combined with traditional chemotherapy (B group). Serum levels of DKK-1 and RANKL were measured by ELISA before and after 4 cycles of chemotherapy. The results indicated that serum DKK-1 level significantly decreased in patients of A group (43.2 µg/L before vs 30.4 µg/L after 4 cycles of chemotherapy), and so did for serum RANKL level in A group (0.83 pmmol/L before vs 0.45 pmmol/L after 4 cycles of chemotherapy). While there was no significant differences in DKK-1 and RANKL serum level before therapy between A and B groups, but there was significant differences in DKK-1 and RANKL levels after 4 cycles of chemotherapy (P < 0.05). It is concluded that bortezomib combined with bisphosphonates obviously reduce the serum levels of DKK-1 and RANKL, thus has beneficial effect on osteolytic lesion.
authors.affiliation: Department of Hematology. Fujian Provincial Hospital, Fujian Medical University, Fuzhou 350001, Fujian Province, China. E-mail:shuangerqu@163.com.
authors.forename: Shuang
authors.initials: S
authors.lastname: Qu
authors.affiliation: Department of Hematology. Fujian Provincial Hospital, Fujian Medical University, Fuzhou 350001, Fujian Province, China.
authors.forename: Li-Sheng
authors.initials: LS
authors.lastname: Liao
authors.affiliation: Department of Hematology. Fujian Provincial Hospital, Fujian Medical University, Fuzhou 350001, Fujian Province, China.
authors.forename: Tian-Nan
authors.initials: TN
authors.lastname: Wei
authors.affiliation: Department of Hematology. Fujian Provincial Hospital, Fujian Medical University, Fuzhou 350001, Fujian Province, China.
authors.forename: Yun
authors.initials: Y
authors.lastname: Lin
authors.affiliation: Department of Hematology. Fujian Provincial Hospital, Fujian Medical University, Fuzhou 350001, Fujian Province, China.
authors.forename: Bin-Yu
authors.initials: BY
authors.lastname: Chen
authors.affiliation: Department of Hematology. Fujian Provincial Hospital, Fujian Medical University, Fuzhou 350001, Fujian Province, China.
authors.forename: Wei-Min
authors.initials: WM
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D001897:Boronic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D000069286:Bortezomib; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000188:drug therapy; D011719:Pyrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D053245:RANK Ligand / Q000097:blood
chemical_list: D001897:Boronic Acids; C501126:DKK1 protein, human; D004164:Diphosphonates; D036341:Intercellular Signaling Peptides and Proteins; D011719:Pyrazines; D053245:RANK Ligand; C505688:TNFSF11 protein, human; D000069286:Bortezomib